Our facility
HIBA Pharma takes pride in operating a state-of-the-art manufacturing facility in KEZAD, Abu Dhabi, UAE, equipped with the latest industry technologies. From the first gram of active ingredient to the final serialised pack, every stage of production takes place under one roof — designed, validated and run to the same uncompromising standard.
And here is catch. Bold text. Italic.
Header 2
Header 3
Centered text
With links

Built to cGMP and international standards
Our facility is being built to comply with cGMP regulations and international standards, ensuring the highest safety, efficacy, and quality standards in every product we manufacture.
Controlled cleanroom environments for sterile and aseptic manufacturing
A dedicated quality control laboratory for release and stability testing
Validated processes and documented procedures across every production line
Serialised packaging lines for full traceability from plant to patient
The only local producer of sterile injectable oncology medicines
We are proud to be the only local facility producing sterile injectable oncology medications. We stand at the forefront of pharmaceutical advancements, reinforcing our commitment to addressing unmet medical needs. Manufacturing these medicines in the UAE shortens supply chains, strengthens regional supply security and brings critical cancer therapies closer to the patients who depend on them.

Capacity and scale
The facility is designed for high-volume production across several dosage forms, with space reserved to grow alongside our portfolio.
16 000 m² current area, with 140 000 m² available for future expansion
6 150 m² of production area and 810 m² of laboratory area
40 million vials, 0.5 billion tablets and 0.25 billion capsules per year
100 million packs per year of packaging capacity
Our commitment
Our mission is clear: to advance pharmaceutical quality and enrich lives by providing safe, effective, and reliable therapies for those who need them most. The KEZAD facility is where that mission becomes medicine.